| Fortinet [FTNT] - Last Close: $53.78 Strong earnings are boosting shares of Fortinet. The company reported better-than-expected earnings on its Q4 earnings report early this morning. Fortinet's EPS came in at $0.44 per diluted share, marking a sharp improvement from last year's $0.25 EPS figure and beating the consensus of $0.44. However, revenues of $1.28 billion narrowly missed the Street's $1.30 billion target. The company's full-year revenue and earnings forecasts also surpassed analysts' expectations. FTNT is this morning's top S&P 500 stock with a 10.4% gain. My Take: FTNT could see more gains if it can break through resistance at $57. Manchester United [MANU] - Last Close: $21.12 Rumors of a potential buyout are boosting shares of Manchester United. The Daily Mail reported late Tuesday that Quatari investors are considering a buyout bid for the European soccer club. The report cited unnamed sources, and Manchester United hasn't responded to requests for comment. In November, the club's owners, the Glazer family, said they had begun looking at strategic options such as a new investment or sale. Last month, Bloomberg reported Qatar Sports Investments was considering a total takeover or a stake in Manchester United. MANU is up 16.1% on news of a potential transaction, making it one of this morning's top stocks. My Take: A buyout bid could give MANU a big boost, and there could still be some upside on the table if a transaction materializes. Evaxion [EVAX] - Last Close: $1.78 Evaxion is on the rise after a promising clinical data release. The clinical-stage biotech announced preclinical proof of concept for a collaborative treatment with Pantherna Therapeutics. According to the release, the preclinical data demonstrated tumor antigens identified by Evaxion's AI platform produced a strong immune response. The therapy also led to a complete inhibition of tumor growth in a preclinical model when delivered using Pantherna's proprietary mRNA platform. News of the preclinical progress sent EVAX to a 33.1% gain, and it's one of this morning's most actively-traded stocks. My Take: This clinical research could produce more catalysts as these applications are refined. This stock could be worth watching. PainReform [PFRX] - Last Close: $0.50 PainReform just scored a big break. The clinical-stage pharma firm announced after Tuesday's closing bell that the Nasdaq offered to extend its window to regain compliance with listing standards. PainReform now has until Aug. 7th, 2023, to regain compliance with Nasdaq's minimum $1 bid price per share requirement. The company was first notified of its failure to maintain compliance on Aug. 10th, 2022. PFRX is one of this morning's top performers with a 49.9% gain. My Take: PFRX could get another big boost if it can successfully regain compliance, and now it has a lot more time to get back in Nasdaq's good graces. GainersAurora Mobile [JG] >> +25.0%New Relic [NEWR] >> +18.2%Know Labs [KNW] >> +17.0%DeclinersSINTX Technologies [SINT] >> (47.4%)Capri Holdings [CPRI] >> (19.3%)Lixte Bio [LIXT] >> (25.4%) CVS Health Corporation [CVS] ... AM
Uber Technologies, Inc. [UBER] ... AM
Eaton Corporation, Plc [ETN] ... AM
CME Group Inc. [CME] ... AM
Brookfield Corporation [BN] ... AM
Emerson Electric Company [EMR] ... AM
Dominion Energy, Inc. [D] ... AM
Yum! Brands, Inc. [YUM] ... AM
Walt Disney Company (The) [DIS] ... PM
O'Reilly Automotive, Inc. [ORLY] ... PM | 